Xylyx Bio awarded $2.45M NIH SBIR grant from NIDDK to facilitate development of effective drugs for fibrotic liver disease
Xylyx Bio, Inc., a regenerative medicine company developing pioneering solutions for tissue and organ modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for liver fibrosis. Fibrosis is a prevalent disease process underlying multiple chronic liver diseases, including alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD affects 100 million people in the U.S. and can lead to cirrhosis, liver failure, and the need for liver transplantation. Read more >>